Sign up
Quantellect · Congress · Trade Detail
NYSE: BMYBristol-Myers Squibb Company
DemocratHouse

Kurt Schrader sold Bristol-Myers Squibb Company (NYSE: BMY)

Kurt Schrader (D-OR), a U.S. Representative, has disclosed 9 trades in Bristol-Myers Squibb Company (BMY) since 2015, 4 purchases and 5 sales, worth an estimated $97K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a sale: Kurt Schrader sold $1,001 - $15,000 of Bristol-Myers Squibb Company (NYSE: BMY) on April 25, 2015. Since that trade, BMY is up +38.78% against the S&P 500 up +314.34%, an outperformance of -275.55%.

Across these filings, Kurt Schrader has been a net seller of BMY (a buy-to-sell ratio of 0.80). The most recent disclosed BMY transaction shown was dated November 8, 2022. Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

BMY trades
9
Disclosed Vol
$97K
Buys
4
44%
Sells
5
56%
Buy / Sell
0.80
ratio
First → Last
2015–2022

Kurt Schrader's BMY trades vs the price

BMY is up +38.78% since Kurt Schrader sold on April 25, 2015, versus +314.34% for the S&P 500.

Performance since this trade

Price change since trade
+38.78%
S&P 500 change since trade
+314.34%
Outperformance vs S&P 500
-275.55%

All Kurt Schrader BMY trades

TradedTypeSizeReturnEst. profit
November 8, 2022SELL$68.51-7.89%
November 8, 2022SELL$68.51-7.89%
February 5, 2020BUY$51.60+22.30%-$304
April 14, 2018SELL$43.69+44.42%
June 4, 2017SELL$39.90+58.14%
January 23, 2017BUY$36.03+75.12%+$2K
December 30, 2016BUY$41.84+50.82%+$638
April 25, 2015SELL$45.47+38.78%
February 8, 2015BUY$40.99+53.92%+$460

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Kurt Schrader & BMY trading FAQ

Is it legal for Kurt Schrader to trade Bristol-Myers Squibb Company (BMY) stock?

Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Kurt Schrader sell BMY?

Kurt Schrader disclosed a sale of $1,001 - $15,000 of Bristol-Myers Squibb Company (BMY) on April 25, 2015, according to public STOCK Act filings.

How has BMY performed since Kurt Schrader's trade?

Since Kurt Schrader sold BMY on April 25, 2015, the stock is up +38.78%, versus +314.34% for the S&P 500 over the same period, an outperformance of -275.55%.

How many times has Kurt Schrader traded BMY?

Kurt Schrader has disclosed 9 BMY trades since 2015 (4 purchases and 5 sales). Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional BMY trades?

Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.

Kurt Schrader's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyKurt Schrader's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.